Precision BioSciences, Inc.
As of Oct 22, 2026, Precision BioSciences is in Stage 3, the topping phase, now in week 5 (since Sep 22, 2026). It closed at $6.78, 26.9% below its 52-week high and above its 200-day average, which is rising.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is DTIL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
DTIL among Biotechnology195th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …195 | DTIL | Stage 3 · wk 5 | 52 | +6.6% |
Precision BioSciences: quick answers
What stage is Precision BioSciences in?
As of Oct 22, 2026, Precision BioSciences (DTIL) is in Stage 3, the topping phase. It entered Stage 3 on Sep 22, 2026 and is in week 5. What the four stages mean
Is Precision BioSciences in an uptrend?
Its uptrend has stalled. Precision BioSciences is in Stage 3, the topping phase that follows an advance. It trades 5.1% above its 200-day average, which is rising.
How far is Precision BioSciences from its 52-week high?
Precision BioSciences closed at $6.78 on Oct 22, 2026, 26.9% below its 52-week high of $9.28. Its 52-week low is $3.57.
How has Precision BioSciences performed over the past year?
As of Oct 22, 2026, Precision BioSciences is down 3.0% over the past year and up 65.4% so far in 2026.
Which sector and industry is Precision BioSciences in?
Precision BioSciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.